IPM Take
Cancer mortality has fallen. That is real progress.
But the report’s harder message is that progress is still distributed unevenly. Where people live, how much they earn, whether they have a usual source of care, and whether a clinical trial exists within reach can still shape their chance of early diagnosis, treatment and survival.
Precision medicine is not precise if geography decides who gets it.
Executive Summary
The American Association for Cancer Research released its Cancer Disparities Progress Report 2026. The report documents major national gains, including a 35% fall in the overall United States cancer death rate since 1991 and a narrowing gap in overall cancer mortality between Black and White populations.
It also identifies persistent inequities. Residents of rural counties are 17% more likely to be diagnosed with colorectal cancer and 27% more likely to die from it than people in metropolitan or urban counties. Cervical cancer mortality is 49% higher among women living in persistent-poverty counties than among women elsewhere. More than 70% of United States counties had no active cancer clinical trials in 2022.
Why it matters
- Patients / advocates: Cancer outcomes should not depend on whether someone lives near a specialist centre, has transport, or can afford follow-up care.
- Public authorities: Screening, referral and clinical-trial access need to be treated as regional infrastructure, not optional services.
- Hospitals / providers: Cancer centres have a role beyond their own walls, including outreach, referral networks and support for rural care.
- Policymakers: Equity needs measurable targets, protected data systems and long-term funding, not only public commitments.
Cancer progress is often presented as a national average.
That is exactly how the gaps disappear.
AACR’s new disparities report shows that the United States has made real gains. Overall cancer mortality has fallen substantially since 1991. Mortality gaps between Black and White populations have narrowed. Some disparities in lung, cervical and stomach cancer outcomes have improved.
Those are achievements worth defending.
But the report also shows what averages conceal. A person living in a rural county is still more likely to be diagnosed with colorectal cancer and more likely to die from it. A woman living in a persistent-poverty county still faces a markedly higher risk of dying from cervical cancer. In 2022, most United States counties had no active cancer clinical trials at all.
This is not only a question of individual behaviour or personal resilience. It is a question of infrastructure: screening availability, primary care access, transport, specialist referral, trial networks, data collection, insurance coverage and trust.
The human consequence is simple. A cancer breakthrough means less when the patient cannot reach the screening programme, the pathology lab, the trial site or the treatment centre.
For IPM, this is the access test that sits beneath every precision-medicine promise. The right treatment is not enough. The right patient must be able to reach it, wherever they live.
